Abstract
Depression affects a large percentage of the general population and can produce devastating consequences to affected individuals, families and society. Although the treatment of depression has been advanced by traditional antidepressants, improvements are needed across several dimensions (e.g., overall treatment efficacy, therapeutic onset time, and side effect profile). The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor has an allosteric modulatory site(s) for which potent positive modulators (potentiators) have been designed. These compounds produce antidepressant-like effects in animal models, increase levels of brain-derived neurotrophic factor (BDNF) and engender neurogenesis in vivo. Although these effects are also produced by traditional antidepressants, AMPA receptor potentiators appear to produce their effects through a novel mechanism.
Keywords: ampa receptors, depression, brain-derived neurotrophic factor, bdnf, neurogenesis
Current Pharmaceutical Design
Title: AMPA Receptor Potentiators as Novel Antidepressants
Volume: 11 Issue: 12
Author(s): A. Alt, J. M. Witkin and D. Bleakman
Affiliation:
Keywords: ampa receptors, depression, brain-derived neurotrophic factor, bdnf, neurogenesis
Abstract: Depression affects a large percentage of the general population and can produce devastating consequences to affected individuals, families and society. Although the treatment of depression has been advanced by traditional antidepressants, improvements are needed across several dimensions (e.g., overall treatment efficacy, therapeutic onset time, and side effect profile). The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor has an allosteric modulatory site(s) for which potent positive modulators (potentiators) have been designed. These compounds produce antidepressant-like effects in animal models, increase levels of brain-derived neurotrophic factor (BDNF) and engender neurogenesis in vivo. Although these effects are also produced by traditional antidepressants, AMPA receptor potentiators appear to produce their effects through a novel mechanism.
Export Options
About this article
Cite this article as:
Alt A., Witkin M. J. and Bleakman D., AMPA Receptor Potentiators as Novel Antidepressants, Current Pharmaceutical Design 2005; 11 (12) . https://dx.doi.org/10.2174/1381612053764814
DOI https://dx.doi.org/10.2174/1381612053764814 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Schizophrenia and the Neglect Syndrome: Parietal Contributions to Cognitive Dysfunction in Schizophrenia
Current Psychiatry Reviews Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design The Glutathione System and its Regulation by Neurohormone Melatonin in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry CCR5-Targeted Hematopoietic Stem Cell Gene Approaches for HIV Disease: Current Progress and Future Prospects
Current Stem Cell Research & Therapy Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights
Current Neuropharmacology p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Molecular and Cellular Control of Dendrite Maturation During Brain Development
Current Molecular Pharmacology Aquaporin and Vascular Diseases
Current Neuropharmacology Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
Current Alzheimer Research Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Meet Our Section Editor
Central Nervous System Agents in Medicinal Chemistry β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry JNK Signalling: A Possible Target to Prevent Neurodegeneration
Current Pharmaceutical Design The Interleukin-1 System: An Attractive and Viable Therapeutic Target in Neurodegenerative Disease
Current Drug Targets - CNS & Neurological Disorders PREPL, a Prolyl Endopeptidase-Like Enzyme by Name Only? – Lessons from Patients
CNS & Neurological Disorders - Drug Targets Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Adenosine Dysfunction in Epilepsy and Associated Comorbidities
Current Drug Targets PDZ Domain-mediated Protein Interactions: Therapeutic Targets in Neurological Disorders
Current Medicinal Chemistry